表紙
市場調査レポート

変形性関節症疼痛:パイプライン製品の分析

Osteoarthritis Pain - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232825
出版日 ページ情報 英文 210 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
変形性関節症疼痛:パイプライン製品の分析 Osteoarthritis Pain - Pipeline Review, H1 2016
出版日: 2016年04月27日 ページ情報: 英文 210 Pages
概要

変形性関節症疼痛は、軟骨の損傷に伴い発症する骨関節炎を伴う最も一般的な症状です。

当レポートでは、変形性関節症疼痛の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

変形性関節症疼痛の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

変形性関節症疼痛:企業で開発中の治療薬

変形性関節症疼痛:大学/機関で研究中の治療薬

変形性関節症疼痛:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

変形性関節症疼痛:企業で開発中の製品

変形性関節症疼痛:大学/機関で研究中の製品

変形性関節症疼痛の治療薬開発に従事している企業

  • AbbVie Inc.
  • Addex Therapeutics Ltd
  • Afferent Pharmaceuticals, Inc.
  • Akron Molecules AG
  • Allergan Plc
  • Amgen Inc.
  • Ampio Pharmaceuticals, Inc.
  • AnaMar AB
  • Antibe Therapeutics, Inc.
  • AskAt Inc.
  • アステラス製薬
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Bone Medical Limited
  • Centrexion Corporation
  • Convergence Pharmaceuticals Ltd.
  • Eli Lilly and Company
  • Elite Pharmaceuticals, Inc.
  • Flexion Therapeutics, Inc.
  • Grunenthal GmbH
  • Iroko Pharmaceuticals, LLC
  • Nektar Therapeutics
  • Nuvo Research Inc.
  • Pfizer Inc.
  • Phosphagenics Limited
  • Pozen, Inc.
  • Purdue Pharma L.P.
  • Regeneron Pharmaceuticals, Inc.
  • Rottapharm SpA

変形性関節症疼痛:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

変形性関節症疼痛:最近のパイプライン動向

変形性関節症疼痛:休止中のプロジェクト

変形性関節症疼痛:開発が中止された製品

変形性関節症疼痛:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7825IDB

Summary

Global Markets Direct's, 'Osteoarthritis Pain - Pipeline Review, H1 2016', provides an overview of the Osteoarthritis Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteoarthritis Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoarthritis Pain and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain
  • The report reviews pipeline therapeutics for Osteoarthritis Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Osteoarthritis Pain therapeutics and enlists all their major and minor projects
  • The report assesses Osteoarthritis Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Osteoarthritis Pain

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Osteoarthritis Pain
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Osteoarthritis Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Osteoarthritis Pain Overview
  • Therapeutics Development
    • Pipeline Products for Osteoarthritis Pain - Overview
    • Pipeline Products for Osteoarthritis Pain - Comparative Analysis
  • Osteoarthritis Pain - Therapeutics under Development by Companies
  • Osteoarthritis Pain - Therapeutics under Investigation by Universities/Institutes
  • Osteoarthritis Pain - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Osteoarthritis Pain - Products under Development by Companies
  • Osteoarthritis Pain - Products under Investigation by Universities/Institutes
  • Osteoarthritis Pain - Companies Involved in Therapeutics Development
    • AbbVie Inc.
    • Addex Therapeutics Ltd
    • Afferent Pharmaceuticals, Inc.
    • Akron Molecules AG
    • Allergan Plc
    • Ampio Pharmaceuticals, Inc.
    • AnaMar AB
    • Antibe Therapeutics, Inc.
    • Aralez Pharmaceuticals Inc.
    • Arena Pharmaceuticals, Inc.
    • Array BioPharma Inc.
    • AskAt Inc.
    • Astellas Pharma Inc.
    • AstraZeneca Plc
    • Axsome Therapeutics, Inc.
    • Biogen, Inc.
    • Boehringer Ingelheim GmbH
    • Bone Medical Limited
    • Carbylan Therapeutics, Inc.
    • Centrexion Corporation
    • Eli Lilly and Company
    • Elite Pharmaceuticals, Inc.
    • Flexion Therapeutics, Inc.
    • GlaxoSmithKline Plc
    • Glenmark Pharmaceuticals Ltd.
    • Grunenthal GmbH
    • Iroko Pharmaceuticals, LLC
    • Novartis AG
    • Nuvo Pharmaceuticals Inc.
    • Pfizer Inc.
    • Phosphagenics Limited
    • pSivida Corp.
    • Purdue Pharma L.P.
    • Regeneron Pharmaceuticals, Inc.
    • Vertex Pharmaceuticals Incorporated
  • Osteoarthritis Pain - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (amlodipine besylate + celecoxib) - Drug Profile
    • (hyaluronate sodium + triamcinolone acetonide) - Drug Profile
    • (lidocaine + tetracaine) - Drug Profile
    • (naltrexone hydrochloride + oxycodone hydrochloride) SR - Drug Profile
    • AAT-008 - Drug Profile
    • adefovir dipivoxil - Drug Profile
    • ADX-71441 - Drug Profile
    • AF-219 - Drug Profile
    • AMAP-102 - Drug Profile
    • Ampion - Drug Profile
    • APD-371 - Drug Profile
    • AQU-010 - Drug Profile
    • ARRY-954 - Drug Profile
    • AS-288640100 - Drug Profile
    • ATB-346 - Drug Profile
    • AXIBU-01 - Drug Profile
    • BI-1026706 - Drug Profile
    • calcitonin - Drug Profile
    • capsaicin - Drug Profile
    • cebranopadol - Drug Profile
    • celecoxib - Drug Profile
    • CGS-125 - Drug Profile
    • CR-4056 - Drug Profile
    • CRB-0089 - Drug Profile
    • duloxetine hydrochloride DR - Drug Profile
    • ELS-130 - Drug Profile
    • EMA-401 - Drug Profile
    • fasinumab - Drug Profile
    • fluticasone propionate - Drug Profile
    • grapiprant - Drug Profile
    • GRC-27864 - Drug Profile
    • GSK-3196165 - Drug Profile
    • ibuprofen - Drug Profile
    • MEDI-7352 - Drug Profile
    • naproxen sodium - Drug Profile
    • NEO-5024 - Drug Profile
    • NEO-5937 - Drug Profile
    • NEO-6860 - Drug Profile
    • OLT-1177 - Drug Profile
    • onabotulinumtoxin A - Drug Profile
    • oxycodone ER - Drug Profile
    • PA-300 DR - Drug Profile
    • PA-65020 - Drug Profile
    • Small Molecule for Osteoarthritis Pain - Drug Profile
    • Small Molecule to Antagonize P2Y14 for Osteoarthritic Pain - Drug Profile
    • Small Molecules for Osteoarthritis Pain - Drug Profile
    • Small Molecules to Block Calcium Ion Channel for Osteoarthritis Pain - Drug Profile
    • Small Molecules to Block Nav1.7 for Osteoarthritis Pain - Drug Profile
    • Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile
    • Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation - Drug Profile
    • Small Molecules to Inhibit PDE2 for Osteoarthritis Pain - Drug Profile
    • tanezumab - Drug Profile
    • triamcinolone acetonide sodium phosphate SR - Drug Profile
    • V-116517 - Drug Profile
    • VG-201 - Drug Profile
    • VX-150 - Drug Profile
    • zoledronic acid - Drug Profile
  • Osteoarthritis Pain - Recent Pipeline Updates
  • Osteoarthritis Pain - Dormant Projects
  • Osteoarthritis Pain - Discontinued Products
  • Osteoarthritis Pain - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Osteoarthritis Pain, H1 2016
  • Number of Products under Development for Osteoarthritis Pain - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Osteoarthritis Pain - Pipeline by AbbVie Inc., H1 2016
  • Osteoarthritis Pain - Pipeline by Addex Therapeutics Ltd, H1 2016
  • Osteoarthritis Pain - Pipeline by Afferent Pharmaceuticals, Inc., H1 2016
  • Osteoarthritis Pain - Pipeline by Akron Molecules AG, H1 2016
  • Osteoarthritis Pain - Pipeline by Allergan Plc, H1 2016
  • Osteoarthritis Pain - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016
  • Osteoarthritis Pain - Pipeline by AnaMar AB, H1 2016
  • Osteoarthritis Pain - Pipeline by Antibe Therapeutics, Inc., H1 2016
  • Osteoarthritis Pain - Pipeline by Aralez Pharmaceuticals Inc., H1 2016
  • Osteoarthritis Pain - Pipeline by Arena Pharmaceuticals, Inc., H1 2016
  • Osteoarthritis Pain - Pipeline by Array BioPharma Inc., H1 2016
  • Osteoarthritis Pain - Pipeline by AskAt Inc., H1 2016
  • Osteoarthritis Pain - Pipeline by Astellas Pharma Inc., H1 2016
  • Osteoarthritis Pain - Pipeline by AstraZeneca Plc, H1 2016
  • Osteoarthritis Pain - Pipeline by Axsome Therapeutics, Inc., H1 2016
  • Osteoarthritis Pain - Pipeline by Biogen, Inc., H1 2016
  • Osteoarthritis Pain - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Osteoarthritis Pain - Pipeline by Bone Medical Limited, H1 2016
  • Osteoarthritis Pain - Pipeline by Carbylan Therapeutics, Inc., H1 2016
  • Osteoarthritis Pain - Pipeline by Centrexion Corporation, H1 2016
  • Osteoarthritis Pain - Pipeline by Eli Lilly and Company, H1 2016
  • Osteoarthritis Pain - Pipeline by Elite Pharmaceuticals, Inc., H1 2016
  • Osteoarthritis Pain - Pipeline by Flexion Therapeutics, Inc., H1 2016
  • Osteoarthritis Pain - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Osteoarthritis Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016
  • Osteoarthritis Pain - Pipeline by Grunenthal GmbH, H1 2016
  • Osteoarthritis Pain - Pipeline by Iroko Pharmaceuticals, LLC, H1 2016
  • Osteoarthritis Pain - Pipeline by Novartis AG, H1 2016
  • Osteoarthritis Pain - Pipeline by Nuvo Pharmaceuticals Inc., H1 2016
  • Osteoarthritis Pain - Pipeline by Pfizer Inc., H1 2016
  • Osteoarthritis Pain - Pipeline by Phosphagenics Limited, H1 2016
  • Osteoarthritis Pain - Pipeline by pSivida Corp., H1 2016
  • Osteoarthritis Pain - Pipeline by Purdue Pharma L.P., H1 2016
  • Osteoarthritis Pain - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016
  • Osteoarthritis Pain - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Osteoarthritis Pain Therapeutics - Recent Pipeline Updates, H1 2016
  • Osteoarthritis Pain - Dormant Projects, H1 2016
  • Osteoarthritis Pain - Dormant Projects (Contd..1), H1 2016
  • Osteoarthritis Pain - Dormant Projects (Contd..2), H1 2016
  • Osteoarthritis Pain - Dormant Projects (Contd..3), H1 2016
  • Osteoarthritis Pain - Dormant Projects (Contd..4), H1 2016
  • Osteoarthritis Pain - Discontinued Products, H1 2016
  • Osteoarthritis Pain - Discontinued Products (Contd..1), H1 2016

List of Figures

  • Number of Products under Development for Osteoarthritis Pain, H1 2016
  • Number of Products under Development for Osteoarthritis Pain - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top